Buradasınız

Anasayfa » Content

Kardiyovasküler Hastalarda Antitrombositik Tedaviye Yanıtın Optik Agregometre ve PFA–100 ile İncelenmesi

Assessment of the Response to Antiplatelet Treatment in Cardiovascular Patients With the Optical Aggregometer and PFA-100

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Many studies have shown that antiplatelet drugs decrease vascular events while some patients experience vascular events despite the antiplatelet treatment. We evaluated the effects of aspirin and clopidogrel on platelet functions and investigated the incidence of antiplatelet drug resistance. The study group consisted of 72 cardiovascular patients using antiplatelet drugs and 22 volunteers. The % maximum aggregation and time to reach maximum aggregation against ADP, collagen and epinephrine were determined. Collagen/Epinephrine and Collagen/ADP cartridges closure times were recorded. Those with platelet functions within the control group limits despite antiplatelet treatment were considered to be resistant to drugs. Aspirin decreased the aggregation response especially against epinephrine and collagen while clopidogrel mainly decreased the aggregation response against ADP. The combined drug group had the lowest maximum aggregation responses. PFA- 100 showed that aspirin increased only Collagen/Epinephrine cartridge’s closure times. The incidence of aspirin resistance was 12/37 and clopidogrel resistance was 1/17. We found no association between the PFA-100 and the aggregometer in determining drug resistance. We observed that antiplatelet drugs had various effects on platelets and that the methods used to assess platelet functions did not show correlation with each other.
Bookmark/Search this post with
Abstract (Original Language): 
Kardiyovasküler hastalarda antitrombositik ilaçların vasküler olayları azalttığı, bazı hastalarda ise antitrombositik tedaviye rağmen vasküler olay yaşayan hastaların olduğu bilinmektedir. Çalışmamızda, aspirin ve klopidogrelin trombositler üzerindeki etkileri değerlendirilmiş ve antitrombositik ilaç direncinin sıklığı araştırılmıştır. Antitrombositik tedavi gören 72 kardiyovasküler hasta ve 22 gönüllü değerlendirildi. Agregometrede ADP, kollajen ve epinefrine karşı % maksimum agregasyon cevapları ve maksimum agregasyona ulaşma süreleri ve PFA– 100 ile Kollajen/Epinefrin ve Kollajen/ADP kartuşlarında kapanma zamanları saptandı. Antitrombositik tedaviye rağmen trombosit fonksiyonları kontrol grubu sınırları içinde olan hastalar aspirine veya klopidogrele dirençli kabul edildi. Agregometre ile ölçülen maksimum agregasyon yanıtlarında aspirinin özellikle epinefrin ve kollajene karşı, klopidogrel’in ise esas olarak ADP’ye karşı olan agregasyonu azalttı- ğı gözlendi. Kombine ilaç grubunda en düşük maksimum agregasyon yanıtları alındı. PFA–100’de aspirin kullanımı yalnızca Kollajen/Epinefrin kartuşu kapanma zamanını uzattı. Aspirin direnci 12/37, klopidogrel direnci 1/17 sıklığında bulundu. PFA–100 ve agregometre arasında ilaç direncinin saptanmasına dair bir ilişki bulunamadı. Antitrombositik ilaçların trombositler üzerinde farklı etkilere sahip oldukları ve trombosit fonksiyonlarının değerlendirilmesinde kullanılan yöntemlerin birbirleriyle ilişkili olmadığı gözlendi.
FULL TEXT (PDF): 
PDF icon arastirmax-kardiyovaskuler-hastalarda-antitrombositik-tedaviye-yanitin-optik-agregometre-pfa-100-ile-incelenmesi.pdf
  • 1
11-17
  • Turkish

REFERENCES

References: 

1. Colman RW, Clowes AW, Goldhaber SZ, Marder VJ, George
JN, (eds). Hemostasis and Thrombosis: Basic Principles and
Clinical Practice. 5th ed. Lippincott Williams & Wilkins; 2006.
2. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002; 324: 71-86.
3. Offermanns S. Activation of Platelet Function Through G
Protein–Coupled Receptors. Circ Res 2006; 99: 1293-1304.
4. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. PlateletActive Drugs: The Relationships Among Dose, Effectiveness,
and Side Effects. Chest 2004; 126; 234-264.
5. Murugappan S, Kunapuli SP. The role of ADP receptors in
platelet function. Front Biosci 2006; 11: 1977-1986.
6. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of
clopidogrel compared with aspirin after myocardial infarction:
Enhanced inhibitory effects of combination therapy. J Am Coll
Cardiol 2000; 36: 699-705.
7. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after iskemic stroke.
Stroke 2003; 34: 849-855.
8. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose
when used alone or in combination with clopidogrel in patients
with acute coronary syndromes. Circulation 2003; 108: 1682-
1687.
9. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and
prevalence of aspirin resistance in patients with cardiovascular
disease. Am J Cardiol 2001; 88: 230-235.
10. Pamukcu B, Oflaz H, Acar RD, et al. The role of exercise on
platelet aggregation in patients with stable coronary artery disease: Exercise induces aspirin resistant platelet activation. J
Thromb Thrombolys 2005; 20: 17-22.
11. Roller RE,Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with
the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13: 277-281.
12. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel
for coronary stenting: Response variability, drug resistance and
the effect of pretreatment platelet reactivity. Circulation 2003;
107: 2908-2913.
13. Michelson AD, Frelinger AL, Furman MI. Resistance to antiplatelet drugs. Eur Heart J Suppl 2006: 8; 53-58.
14. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance:
Consideration and management. J Interven Cardiol 2006; 19:
439-448.
15. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A
prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
16. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA–100 in patients with coronary artery disease. Thromb Res 2003; 108: 37-42.
17. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent
atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
18. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM,
Ostgaard RA. Description of an in vitro Platelet Function Analyzer-PFA-100. Semin Thromb Hemost 1995; 21: 106-112.
19. Favaloro EJ. Utility of the PFA–100 for assessing bleeding
disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001: 7; 170-179.
20. Jarvis GE. Platelet Aggregation: Turbidimetric Measurements.
In: Gibbins JM, Mahaut-Smith MP, editors. Platelets and
Megakaryocytes: Volume 1, Functional Assays. New Jersey:
Humana Press Inc; 2004. pp. 65-76.
21. Salat A, Kroess S, Felfernig-Boehm D, et al. Comparison of in
vitro closure time (PFA–100) with whole blood electrical aggregometry and platelet surface antigen expression in healty
volunteers. Thromb Res 2002; 105: 205-208.
22. Peters AJ, Borries M, Gradaus F, Jax TW, Schoebel FC,
Strauer BE. In vitro bleeding test with PFA-100—Aspects of
controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb
Thrombolys 2001; 12: 263-272.
23. Gormsen J, Nielsen JD, Dalsgaard J, Andersen LA. ADPinduced platelet aggregation in vitro in patients with ischemic
heart disease and peripheral thromboatherosclerosis. Acta Med
Scand 1977; 201: 509-513.
24. Eikelboom JW, Hankey GJ. Aspirin resistance: Anew independent predictor of vascular events? J Am Coll Cardiol 2003;
41: 966-968.

Thank you for copying data from http://www.arastirmax.com